louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02380196: The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
Official title: The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-small Cell Lung Cancer (NSCLC)
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2015-03-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Non-small cell lung cancer (NSCLC)

Brief summary: The primary objective of this study is to determine whether circulating tumor cells (CTCs) can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage I) non-small cell lung cancer (NSCLC). Patients scheduled to undergo surgical intervention will have blood samples obtained to test for CTCs. Presence of CTCs will be compared to final pathologic diagnosis based on surgical specimens to assess the sensitivity of using CTCs alone to make a definitive diagnosis.


Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of stage I NSCLC a. Only patients with a pathologically confirmed NSCLC will be retained for data analysis b. Should pathologic diagnosis reveal a more advanced stage, these subjects will remain in the study
2. 18 years of age
3. Ability to read and sign informed consent
4. Both men and women and members of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

1. Prior cancer diagnosis, excluding previously treated non-melanoma skin cancer
2. Prior or ongoing treatment of the clinically diagnosed cancer

Primary outcomes:
measure: Number of adverse events
timeFrame: 2.5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Charles Simone, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02692196: Fronto-limbic Functional Connectivity Via Real-time fMRI Neurofeedback
Official title: Voluntary Regulation of Fronto-limbic Functional Connectivity: A Proof-of-concept Real-time fMRI Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Neurofeedback
Emotion processing
Real-time
fMRI
Lead sponsor: University of Electronic Science and Technology of China
Sponsor class: OTHER
First posted: 2016-02-25
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Real-time fMRI neurofeedback training induced volitional control of brain activity and connectivity could help individuals to gain better control over their emotions.

Detailed description: In the present proof-of-concept study, investigators plan to evaluate whether real-time fMRI neurofeedback training can enable individuals to gain volitional control over their fronto-limbic circuitry. Given that this circuitry has been abundantly implicated in emotional perception and regulation this could facilitate emotional control. Suitable participants underwent fronto-limbic connectivity feedback training and sham training in a cross over design. During both trainings participants are instructed to regulate the neural indices during feedback. We expect that receiving fronto-limbic feedback enhances emotion regulation during the training.

Eligibility criteria: Inclusion Criteria:

* healthy subjects without past or current psychiatric or neurological disorders

Exclusion Criteria:

* pregnant, taking oral contraceptives

Primary outcomes:
measure: Neural indices of training success
timeFrame: three days
measure: Training-induced changes in emotion related processing
timeFrame: three days
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu
country: China
facility: School of Life Science and Technology, University of Electronic Science and Technology of China
state: Sichuan
Study officials:
affiliation: School of Life Science and Technology, University of Electronic Science and Technology of China
name: Benjamin Becker, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06113796: Economic Analysis of Robotic Rectal Resection in German Health Care System
Official title: Economic Analysis of Robotic Rectal Resection in German Health Care System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rectal Cancer
Keywords: Robotic Surgery
Rectal Cancer
Low anterior Resection
Abdominoperineal rectal extirpation
Economic analysis
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor class: OTHER
First posted: 2023-11-02
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients operated robotically-assisted between 01/2018 and 12/2019 for rectal cancer are suitable for inclusion.

Brief summary: Analysis of cost effectiveness of robotic rectal resection, either sphincter preserving or abdominoperineal extirpation, in the German diagnosis related groups (DRG) system.

Detailed description: Robotic surgery has many well-known benefits for patients and surgeons, while it comes with higher acquisition and maintenance costs. On the other hand, a higher proportion of minimally invasive procedures can save costs by reducing complications, decreasing hospital stays due to lower morbidity, and saving personnel.

To what extent can robotic surgery be cost-covering or even profitable, depending on the postoperative course? This question is investigated under the conditions of the German DRG system.

Eligibility criteria: Inclusion Criteria:

* 18y
* histologically proven rectal cancer with curative therapeutic approach
* suitable for minimally-invasive surgery

Exclusion Criteria:

* no rectal cancer
* primary open surgery

Primary outcomes:
measure: Costs of treatment
timeFrame: 1 year
Secondary outcomes:
measure: Major Complication
timeFrame: 30 days postoperatively
measure: Length of Hospital Stay
timeFrame: 3 months
measure: 30-days Readmission
timeFrame: 30 days
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: University of Hamburg Medical Institutions
Study officials:
affiliation: Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf
name: Daniel Perez, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02480296: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers
Official title: A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple Oral Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MYK-461 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: MyoKardia, Inc.
Sponsor class: INDUSTRY
First posted: 2015-06-24
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to establish safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of MYK-461 in human subjects. This is a randomized, double-blind, placebo-controlled, sequential group, multiple ascending (oral tablet) dose study in healthy volunteers aged 18-55 years.


Eligibility criteria: Inclusion Criteria:

* Normal body mass index (BMI)
* Normal LVEF
* Normal electrocardiogram (ECG)
* Females must be non pregnant, non lactating and, if sexually active, be using an acceptable birth control method from the time of first dose through 3 months after the last dose of study drug

Exclusion Criteria:

* Any structural abnormalities on echocardiography
* Positive results of HIV test and/or seropositive for HCV or HBV

Primary outcomes:
measure: Safety as measured by the incidence of adverse events
timeFrame: 63 days
Secondary outcomes:
measure: Determination of pharmacokinetic parameters
timeFrame: 63 days
measure: Determination of pharmacokinetic parameters
timeFrame: 63 days
measure: Determination of pharmacokinetic parameters
timeFrame: 63 days
measure: Determination of pharmacokinetic parameters
timeFrame: 63 days
measure: Characterize pharmacodynamic parameters
timeFrame: 63 days
measure: Characterize pharmacodynamic parameters
timeFrame: 63 days
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Nucleus Network
state: Victoria
Study officials:
affiliation: MyoKardia, Inc.
name: Michael Grimm, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00935896: High Tidal Volume Induces Inflammation In Normal Lungs
Official title: Mechanical Ventilation With High Tidal Volume Induces Inflammation In Patients Without Lung Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mechanically Ventilated Patients
Normal Lungs
Keywords: Ventilator-associated lung injury
Tumor necrosis factor-alpha
Interleukin-8
Mechanical ventilation
Low tidal volume ventilation
Normal lungs
Lead sponsor: Federal University of Rio Grande do Sul
Sponsor class: OTHER
Collaborators: name: Programa de Pós-Graduação em Clínica Médica
name: Faculdade de Medicina
First posted: 2009-07-09
Enrollment: 20
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: SUPPORTIVE_CARE

Brief summary: Objective: To compare the effects of a protective versus a conventional ventilatory strategy, on systemic and in lung production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-8 (IL-8) in patients without lung disease.

Hypothesis: High tidal volumes induce inflammation in patients without lung disease Design: Prospective control-randomized study. Patients and Setting: Twenty patients without lung disease and submitted to mechanical ventilation admitted to one trauma and one general adult intensive care unit of two different university hospitals.

Interventions: Patients were randomized to receive mechanical ventilation either with tidal volume (VT) of 10-12 ml/kg predicted body weight (high VT group) or with VT of 5-7 ml/kg predicted body weight (low VT group) with an O2 inspiratory fraction (FIO2) enough to keep arterial oxygen saturation \> 90% with positive end-expiratory pressure (PEEP) of 5 cmH2O during 12 hours after admission to the study.


Eligibility criteria: Inclusion Criteria:

1. age ≥ 16 years;
2. anticipated survival \> 24 hours;
3. need for mechanical ventilation for at least 12 hours and
4. hemodynamic stability (MAP\>65 mmHg, HR\<100 beats/min, diuresis \> 1 ml/kg/h, no catecholamine requirement or fluid challenge).

Exclusion Criteria:

1. history of any lung disease, use of immunosuppressive medication, recent infections, previous thromboembolic disease, recent ventilatory support, and participation in another clinical trial. Absence of lung disease was defined by the following clinical criteria: (a) no evidence of respiratory infection (white blood cell count \<10x103/µl, temperature \> 380C, purulent sputum), (b) normal chest roentgenogram, (c) PaO2/FIO2 ratio \> 300, (d) and a normal clinical respiratory history.

Primary outcomes:
measure: Lung cytokines in mechanically ventilated patients
timeFrame: 30 months
Secondary outcomes:
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Complexo Hospitalar Santa Casa
state: RS
city: Porto Alegre
country: Brazil
facility: Hospital de Pronto Socorro
state: RS
Study officials:
References:
Clinical trial NCT00480896: Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment
Official title: Clinical Study on Tacrolimus Ointment Over the Long-term. "CONTROL Study - Children"
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dermatitis, Atopic
Keywords: Dermatitis, atopic
Tacrolimus
Child
treatment outcomes
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2007-05-31
Enrollment: 250
Sex: ALL
Minimum age (years): 2
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and prevent, delay, and reduce flares.


Eligibility criteria: Inclusion Criteria:

* Male or female patient of any ethnic group
* Patient was at least 2-15 years old and suffered from mild to severe atopic dermatitis (Rajka/Langeland score of at least 3)

Exclusion Criteria:

* Patient had a genetic epidermal barrier defect such as Netherton's syndrome or generalised erythroderma
* Patient had a clinically significant skin infection on the affected (and to be treated) area

Primary outcomes:
measure: Number of exacerbations of atopic dermatitis requiring intervention.
timeFrame: 12 months
Secondary outcomes:
measure: Time to first exacerbation requiring intervention; exacerbation treatment days, periods and time to first exacerbation; physician and patient assessment of affected area, treatment response; quality of life; global response.
timeFrame: 12 months
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
city: Brno
country: Czech Republic
city: Praha
country: Czech Republic
facility: 3 Sites
city: Helsinki
country: Finland
city: Nantes
country: France
city: Paris
country: France
city: Dusseldorf
country: Germany
city: Frankfurt
country: Germany
city: Kiel
country: Germany
city: Mahlow
country: Germany
city: Budapest
country: Hungary
city: Bergamo
country: Italy
city: Parma
country: Italy
city: Roma
country: Italy
city: Amsterdam
country: Netherlands
city: Groningen
country: Netherlands
city: Nijmegen
country: Netherlands
city: Utrecht
country: Netherlands
city: Porto
country: Portugal
city: Barcelona
country: Spain
city: Birmingham
country: United Kingdom
city: London
country: United Kingdom
Study officials:
affiliation: Universitätsklinikum Frankfurt Zentrum für Dermatologie
name: Use Central Contact
role: PRINCIPAL_INVESTIGATOR
References:
citation: Thaci D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, van der Valk P, Buckova H, Sebastian M, Schuttelaar ML, Ruzicka T; European Tacrolimus Ointment Study Group. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008 Dec;159(6):1348-56. doi: 10.1111/j.1365-2133.2008.08813.x. Epub 2008 Sep 6.
Clinical trial NCT05002296: Effect of Rotatory Upper Cervical Manipulation on Reflex Cervical Vertigo
Official title: Effect of Rotatory Upper Cervical Manipulation on Reflex Cervical Vertigo in Chronic Mechanical Neck Pain Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Vertigo
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-08-12
Enrollment: 40
Sex: ALL
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cervical reflex vertigo is a non-common cause of vertigo, caused by decreased afferent input from the upper three cervical segments to vestibular nuclei.


Eligibility criteria: Inclusion Criteria:

* cervical pain
* vertigo

Exclusion Criteria:

* severe osteoporosis
* blood circulation problem

Primary outcomes:
measure: pain intensity seems to be improved
timeFrame: 3 monthes
measure: vertigo seems to be significantly improved
timeFrame: 3 monthes
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: faculty of physical therapy Cairo university
Study officials:
affiliation: lecturer at faculty of physiotherapy, Cairo university
name: Abdelaziz Elsherif, lecturer
role: STUDY_DIRECTOR
affiliation: professor at faculty of medicine
name: Amr Hassan, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03593096: Acute Exposure to High Altitude on Heart Rate and Ventilation During Exercise
Official title: Acute Exposure to Hypoxia in Precapillary Pulmonary Hypertension: Physiological and Clinical Effects at Rest and During Exercise
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pulmonary Hypertension
Keywords: High Altitude
Exercise
Ventilation
Heart rate
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2018-07-19
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Including a baseline assessment and assessments at Low alitude and High altitude
Primary purpose: PREVENTION

Brief summary: Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (Säntis; 2500m above sea level) on heart rate and Ventilation changes under exercise.

Detailed description: Low altitude baseline measurements will be performed in Zurich (460m asl) including Echocardiography, Right heart catheterization, 6MWT, pulmonary function test, clinical assessment and blood gas Analysis.

Randomly assigned to the order of testing, the participants will be tested in Low Altitude (Zurich, 470m) and at High Altitude (2500m).

During the exposure to High Altitude (2500m) and Low Altitude (Zurich; 470m) of up to 5 hours, the participants' heart rate and Ventilation will be compared under exercise.

Eligibility criteria: Inclusion Criteria:

* Informed consent
* PH diagnosed according to internation Guidelines: mPAP ≥ 25 mmHg along with a PAWP ≤15 mmHg during right heart catheterization at the time of Initial diagnosis
* PH class 1 (PAH) or 4 (CTEPH)
* Stable condition, on the same medication for \> 4 weeks
* Patient live permanently at an altitude \< 1000m asl.

Exclusion Criteria:

* Resting PaO2 ≤7.3 kPA corresponding to the requirement of long-term oxygen therapy \> 16hour daily (nocturnal oxygen therapy alone is allowed)
* Severe daytime hypercapnia (pCO2 \> 6.5 kPa)
* Susceptibility to high altitude related diseases (AMS, HAPE, etc.) based on previous experienced discomfort at altitudes.
* Exposure to an altitude \>1500m for ≥3 nights during the last 4 weeks before the study participation
* Residence \> 1000m above sea level
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with Walking disability
* Women who are pregnant or breast feeding

Primary outcomes:
measure: Heart rate under exercise
timeFrame: within 5 hours
Secondary outcomes:
measure: Ventilation under exercise
timeFrame: within 5 hours
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Respiratory Clinic, University Hospital of Zurich
Study officials:
affiliation: University of Zurich
name: Silvia Ulrich, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00389896: A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: HDL Cholesterol
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2006-10-19
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see how well simvastatin raises HDL levels in patients with Type 2 Diabetes.


Eligibility criteria: Inclusion Criteria:

* Patient has stable Type 2 diabetes mellitus at Visit 1.
* Patient meets screening criteria based on Visit 1 lab tests

Exclusion Criteria:

* Patient is pregnant, breastfeeding, or at risk of becoming pregnant
* Patient has heart disease, uncontrolled high blood pressure, or other significant disease
* Patient is taking prohibited medication(s) and is unable to stop taking them for the duration of the study

Primary outcomes:
measure: HDL-C raising effects after 6 weeks
timeFrame: 6 weeks
Secondary outcomes:
measure: Effect on other lipids and lipoproteins at 6 weeks
timeFrame: 6 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. Curr Med Res Opin. 2006 Feb;22(2):343-50. doi: 10.1185/030079906X80521.
citation: Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Curr Med Res Opin. 2004 Jul;20(7):1087-94. doi: 10.1185/030079904125004105.
Clinical trial NCT00560196: Pain Processing in Anxiety and Depression
Official title: Pain, Anxiety and Depression in Patients With Panic Anxiety Disorders Without Pain or Depression Without Pain Compared With Healthy Volunteers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain
Anxiety
Depression
Keywords: Neuropathic pain
Chronic pain
Depression
Anxiety
Lead sponsor: Danish Pain Research Center
Sponsor class: OTHER
First posted: 2007-11-19
Enrollment: 71
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatient clinic Primary care clinic Community sample

Brief summary: The purpose of the study is to investigate pain, anxiety and depression in patients with panic anxiety disorders without pain or depression without pain compared with healthy volunteers


Eligibility criteria: Inclusion Criteria:

* Patients with panic disorder or depression

Exclusion Criteria:

* Treatment with antidepressants, anticonvulsants or any other pain medication except paracetamol, SSRI and benzodiazepines
* Serious or unstable medical disease
* Prior or present diagnosis of mania, bipolar or psychotic disorder, delirium, suicidal, drug and alcohol dependence, severe agitation
* Patients who cannot cooperate and do not understand Danish

Primary outcomes:
measure: Quantitative sensory testing
timeFrame: 3-4 hours
Secondary outcomes:
measure: Symptom checklist 92
timeFrame: 3-4 hours
measure: Hamilton Depression and Anxiety Rating Scale
timeFrame: 3-4 hours
measure: Major Depression Inventory
timeFrame: 3-4 hours
measure: GAD-10 Anxiety Scale
timeFrame: 3-4 hours
measure: Health Survey SF-36
timeFrame: 3-4 hours
measure: McGill Pain Questionnaire
timeFrame: 3-4 hours
measure: Sweat test
timeFrame: 3-4 hours
measure: Heart rate variability testing
timeFrame: 3-4 hours
measure: Coping Strategy Questionnaire
timeFrame: 3-4 hours
measure: Pain Catastrophizing Scale
timeFrame: 3-4 hours
measure: Pain rating (VAS)
timeFrame: 3-4 hours
measure: Interview
timeFrame: 3-4 hours
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Danish Pain Research Center, Aarhus University Hospital
Study officials:
affiliation: Danish Pain Research Center, Aarhus University Hospital
name: Lise Gormsen, MD
role: PRINCIPAL_INVESTIGATOR
References: